Do you have any questions?
Download Emerge ARK ETF Facts Download Prospectus

Investment Objectives

Emerge ARK Genomics and Biotech ETF is an actively managed mutual-fund that seeks to achieve long-term growth of capital by investing primarily, under normal circumstances, in the global equity securities of companies that are, or are expected to be, focused on extending and enhancing the quality of human and other life through technological and scientific developments, improvements and advancements in biotech and genomics

Profile of an Innovator : Portfolio Manager

Catherine Wood founded ARK Investment Management in 2014. She spent the previous 12 years at AllianceBernstein as Chief Investment Officer of Global Thematic Strategies that had over US$5 billion in assets under management. Before AllianceBernstein, she worked for 18 years with Jennison Associates as Chief Economist, Equity Research Analyst, Portfolio Manager and Director. Catherine started her career in Los Angeles at the Capital Group as an Assistant Economist.

Why Invest?

Exposure to Innovation: Aims to achieve thematic multi-capitalization exposure to innovation across sectors. ARK believes the securities held in this fund present the best risk-reward opportunities from ARK’s innovation-based themes.

Growth Potential: Aims to capture long-term growth, with low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.

Tool for Diversification: Active stock selection results in little overlap with traditional indices. This mutual fund can be a complement to traditional value/growth strategies.

Grounded in Research: Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.

Top 10 Holdings

As at Sept 30, 2021

Teladoc Health Inc.7.0%
Exact Sciences Corporation5.3%
Pacific Biosciences of California, Inc.5.0%
Vertex Pharmaceuticals Incorporated4.3%
Ionis Pharmaceuticals, Inc.4.0%
Fate Therapeutics Inc.3.9%
Regeneron Pharmaceuticals, Inc.3.6%
Twist Bioscience Corporation3.3%
Takeda Pharmaceutical Company Limited3.1%
Accolade Inc.3.1%
Click Here to Download the Full Holdings Report as at Sept 30, 2021

Series A Fund Facts

FUND CODE CAD: ECI200
FUND CODE USD: ECI201
MIN INVESTMENT: n/a
TRAILER FEE: 1%
COMISSION FEE: Up to 5%

INCEPTION DATE: 6.22.2021
MANAGEMENT FEE: 1.80%
CURRENCY: CAD/USD
SUB-ADVISORS: ARK Investment Management LLC

FEES
Management Fee: 1.80%
MER: 2.15%*

*as expected for 2021, please reference emergecm.ca for information regarding the MER for each ETF.

Series F Fund Facts

FUND CODE CAD: ECI210
FUND CODE USD: ECI211
MIN INVESTMENT: $1000 (waived off for self- directed accounts)

INCEPTION DATE: 6.22.2021
MANAGEMENT FEE: 0.80%
CURRENCY: CAD/USD
SUB-ADVISORS: ARK Investment Management LLC

FEES
Management Fee: 0.80%
MER: 1.15%*

*as expected for 2021, please reference emergecm.ca for information regarding the MER for each ETF.

Series O Fund Facts

FUND CODE CAD: ECI220
FUND CODE USD: ECI221
MIN INVESTMENT: $20,000,000
INCEPTION DATE: 6.22.2021
CURRENCY: CAD/USD
SUB-ADVISORS: ARK Investment Management LLC
FEES: Negotiable
Sector Allocation

As at September 30, 2021

  • Health Care 95.8%
  • Information Technology 2.8%
  • Financials 1.2%
Fund Characteristics

As at Sept 30, 2021

  • Americas 92.7%
  • Europe 3.4%
  • Asia 3.1%
  • Middle East 0.4%

Commissions, management fees, brokerage fees and expenses may be associated with an investment in ETFs. Before investing, you should carefully consider each mutual fund series investment objectives, strategies, risks, charges and expenses. This and other information are in the Mutual Fund Series’s and ETFs prospectus, which may be obtained by visiting www.emergecm.ca or www.sedar.com. Please read the Mutual Fund Series and ETF prospectuses carefully before you invest. An investment in a Mutual Fund Series and/or ETF is subject to risks and you can lose money on your investment. Detailed information regarding the specific risks of the Mutual Fund Series and/or ETF can be found in the prospectus. There can be no assurance that the ETF will achieve its investment objective. The Mutual Funds or ETFs portfolio is more volatile than broad market averages. Mutual Funds or ETFs are not guaranteed. Their values change frequently. Past performance may not be repeated. The statements contained in this document are based on information believed to be reliable and are provided for information purposes only. Where such information is based in whole or in part on information provided by third parties, we cannot guarantee that it is accurate, complete or current at all times. This document does not provide investment, tax, or legal advice, and is not an offer or solicitation to buy. Graphs and charts are used for illustrative purposes only and do not reflect future values or returns on investment. Particular investment strategies should be evaluated according to an investor’s investment objectives and tolerance for risk. Emerge Canada Inc. and related entities are not liable for any error or omission in the information or for any loss or damage suffered. Certain statements in this marketing profile include forward-looking statements, including statements identified by the expressions “believe”, “will” and similar expressions to the extent they relate to the Emerge ETF, Emerge. These forward-looking statements are subject to a number of risks and uncertainties and are based on several assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from current expectations. Forward-looking statements are not guarantees of future results. The top ten holdings, sector weights, geographic allocations, and market capitalization are included to illustrate examples of the securities and sectors, geographics and market caps that the fund held as at a particular date and may not be representative of the fund’s current or future investments and may change at any time